The Pathology of US Health Care—The Example of Weight Loss Medications

August 15, 2024, Paper: "Glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists are among the most promising medical innovations of the past few decades. If the weight reduction and reduced chronic disease impairment that has been reported for these drugs is sustained over time, these medications have the potential to markedly improve population health. And yet, the US health care system is ill-equipped to manage them financially, and thus clinically. The result is confusion, uneven use, and the potential for huge disparities in health."